[
  {
    "ts": null,
    "headline": "DexCom, Inc. (DXCM) Continues to Focus on Glucose Sensors Leadership",
    "summary": "DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom, Inc. (NASDAQ:DXCM) from $99 to $95. The analyst maintained his Buy rating on the stock. Plovanic noted that fourth-quarter results and 2026 outlook […]",
    "url": "https://finnhub.io/api/news?id=e4dc26cbdbb29681a6a3801d7c7e126f6e1197823c1e9151f57edba3fa88f26b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771879214,
      "headline": "DexCom, Inc. (DXCM) Continues to Focus on Glucose Sensors Leadership",
      "id": 139188138,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom, Inc. (NASDAQ:DXCM) from $99 to $95. The analyst maintained his Buy rating on the stock. Plovanic noted that fourth-quarter results and 2026 outlook […]",
      "url": "https://finnhub.io/api/news?id=e4dc26cbdbb29681a6a3801d7c7e126f6e1197823c1e9151f57edba3fa88f26b"
    }
  },
  {
    "ts": null,
    "headline": "Did DexCom's (DXCM) Strong 2025 Results and Buybacks Just Reframe Its 2026 Growth Story?",
    "summary": "In February 2026, DexCom reported fourth-quarter 2025 sales of US$1,259.6 million and full-year 2025 sales of US$4,662 million, with net income rising to US$267.3 million for the quarter and US$836.3 million for the year, and reaffirmed its 2026 revenue guidance of US$5.16–US$5.25 billion. The company also completed a US$499.99 million share repurchase program and highlighted strong uptake of its 15-day G7 sensor, underscoring management’s confidence in product adoption and capital...",
    "url": "https://finnhub.io/api/news?id=79a1971e0876e0fa4da77a04351e2879f30999678f0656db4e14b02655ff1cb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771848538,
      "headline": "Did DexCom's (DXCM) Strong 2025 Results and Buybacks Just Reframe Its 2026 Growth Story?",
      "id": 139183850,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "In February 2026, DexCom reported fourth-quarter 2025 sales of US$1,259.6 million and full-year 2025 sales of US$4,662 million, with net income rising to US$267.3 million for the quarter and US$836.3 million for the year, and reaffirmed its 2026 revenue guidance of US$5.16–US$5.25 billion. The company also completed a US$499.99 million share repurchase program and highlighted strong uptake of its 15-day G7 sensor, underscoring management’s confidence in product adoption and capital...",
      "url": "https://finnhub.io/api/news?id=79a1971e0876e0fa4da77a04351e2879f30999678f0656db4e14b02655ff1cb7"
    }
  }
]